Makker, Vicky
Memorial Sloan Kettering Cancer Center
3 papers on CoChatORCID 0000-0001-9793-7614
Most cited papers
- Verified
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer
Makker, V., Taylor, M. H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., DiSimone, C., et al. (2020) · Journal of Clinical Oncology
Endometrial and Cervical Cancer TreatmentsCancer Immunotherapy and Biomarkers
Cited by 522
- Verified
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., et al. (2019) · The Lancet Oncology
Endometrial and Cervical Cancer TreatmentsCancer Immunotherapy and Biomarkers
Cited by 476
- Verified
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology
HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations
Cited by 151
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free